12 research outputs found
EVALUATION OF XANTHINE OXIDASE INHIBITORY ACTIVITY BY FLAVONOIDS FROM PONGAMIA PINNATA LINN
ABSTRACTObjective: Flavonoids from the crude seeds extract of Pongamia pinnata L., dried fruit powder of Morinda citrifolia L., bark of Mangifera indica L., andrhizome of Zingiber officinale Rosc. were screened for xanthine oxidase (XO) inhibition at different concentration. The inhibitory potential of quercetinand allopurinol were used for the determination of 50% inhibitory concentration (IC50) and Ki values.Methods: Isolation of flavonoids from the plant extracts was processed by column chromatography and tested for XO inhibitory activity in the rangeof 6-800 μg/ml.Results: The results demonstrated that optimized flavonoids extract of P. pinnata L. exhibited promising XO inhibition. P. pinnata L., M. indica L., andZ. officinale Rosc. had IC50 in the concentration of 8.74 mM, 1.09 mM, 5.4 mM and Ki 0.35 mM, 1.73 mM, 2.7 mM, respectively.Conclusion: The study showed that plant species under investigation exhibited XO inhibition by optimized flavonoid extract. P. pinnata L. indicatedpromising XO inhibition compared to other plant extracts. Flavonoids can be used as a potent inhibitor of XO an alternative to allopurinol.Keywords: Xanthine oxidase, Quercetin, Allopurinol, Pongamia pinnata, Oxidative stress
PHOSPHOLIPASE A 2 PLASMA ELASTASE ACTIVITY IN PRE AND POST PARTUM OF PRE-ECLAMPTIC WOMEN
Objective: The objectives of the present study were to evaluate the activity of phospholipase A 2 , plasma elastase enzymes and to assess relation withan inflammatory marker high sensitive C-reactive protein (hs-CRP) in nonpregnant before and after delivery of normotensive pregnant and preeclampticwomen.Methods: The study population consists of three groups: Nonpregnant (Group 1, n=57), normotensive pregnant (Group 2, n=57), and pre-eclampticwomen (Group 3, n=57). Groups 2 and 3 were followed after delivery within 48 hrs. Phospholipase A , plasma elastase, and hs-CRP levels were determined spectrophotometrically.Results: The plasma elastase, phospholipase A 22 activity, and hs-CRP were elevated in pre-eclampsia significantly (p<0.05), nonsignificant rise innormotensive pregnant before delivery condition compared to nonpregnant women. However, plasma elastase in normal pregnancy and pre-eclampsiawere decreased by 1.2- and 2.07-fold, respectively, after delivery. Whereas phospholipase A and hs-CRP found to be nonsignificantly decreased in thepostdelivery status of the both the groups. Receiver operating characteristics curve analysis showed that elastase enzyme has diagnostic importance to assess inflammation on the basis of area under curve (0.758).2Conclusion: Our research findings generated knowledge about raised level of plasma elastase enzyme by neutrophil degranulation represents inflammation in pre-eclampsia. Elevated elastase, phospholipase AKeywords: Elastase, High sensitive C - reactive protein, Phospholipase A2 with hs-CRP in pre-eclampsia serves as indicators of inflammation., Pre-eclampsia.2 Objective:Theobjectivesofthepresentstudywere toevaluatetheactivityofphospholipaseA,plasmaelastaseenzymesand toassessrelationwith an inflammatorymarkerhighsensitiveC-reactiveprotein(hs-CRP)innonpregnantbeforeandafterdeliveryofnormotensivepregnantandpre- eclamptic women. 2 Methods:Thestudypopulationconsistsofthreegroups:Nonpregnant(Group1,n=57),normotensivepregnant(Group2,n=57),andpre-eclamptic women(Group3,n=57).Groups2and3werefollowedafterdeliverywithin48hrs.PhospholipaseA,plasmaelastase,andhs-CRPlevelsweredetermined spectrophotometrically. 2 Results:Theplasmaelastase,phospholipaseA  activity,andhs-CRPwereelevatedinpre-eclampsiasignificantly(p<0.05),nonsignificantrisein normotensivepregnantbeforedeliveryconditioncomparedtononpregnantwomen.However,plasmaelastaseinnormalpregnancyandpre-eclampsia2 weredecreasedby1.2-and2.07-fold,respectively,afterdelivery.WhereasphospholipaseA  andhs-CRPfoundtobenonsignificantlydecreasedinthe postdelivery status of the both the groups. Receiver operating characteristics curve analysis showed that elastase enzyme has diagnostic importance to assess inflammation on the basis of area under curve (0.758). 2 Conclusion: Ourresearchfindingsgeneratedknowledgeaboutraisedlevelofplasmaelastaseenzymebyneutrophildegranulationrepresents inflammation in pre-eclampsia. Elevated elastase, phospholipase A  with hs-CRP in pre-eclampsia serves as indicators of inflammation.2 Keywords:Elastase, High sensitive C - reactive protein, Phospholipase A, Pre-eclampsia
Impact of REM sleep deprivation and sleep recovery on circulatory neuroinflammatory markers
Objectives: Sleep loss may contribute to neuroinflammation, which might increase
neuroinflammatory markers such as neuron-specific enolase (NSE), creatine kinase-brain fraction
(CK-BB), lactate dehydrogenase brain fraction (LDH-BB) in blood. Hence, we evaluated the effect
of REM sleep deprivation and recovery on these markers. Material and Methods: Twenty-four
adult male Sprague Dawley rats were grouped as control, environmental control, REM sleep
deprivation, and 24 hour sleep recovery. The rats were sleep deprived for 72 hours and recovered for
24 hours. NSE, CK-BB, and LDH-BB levels in serum were measured using ELISA. Results: The
serum NSE, CK-BB, and LDH-BB were significantly higher in 72 hour sleep deprived group
compared to control (p<0.01). After 24 hours of sleep recovery, the levels of NSE, CK-BB, and
LDH-BB were comparable to control (p>0.05). Discussion: REM sleep deprivation increased
serum NSE, CK-BB, and LDH-BB, which might be due to neural damage. However, 24 hours of
sleep recovery restored these markers
Apelin 13 and Blood Pressure, Is there any Association in Pre-eclampsia? - A Case-control Study
Introduction: Pre-eclampsia is a pregnancy specific disorder,
characterised by the onset of hypertension and proteinuria. Preeclampsia is the leading cause of maternal, perinatal morbidity
and mortality. The exact cause of pre-eclampsia is not known
clearly and needs to be explored.
Aim: To evaluate the maternal serum apelin 13 levels among
pre-eclampsia and healthy pregnant women and also, to find
the association between apelin 13 and blood pressure.
Materials and Methods: A case-control study was conducted
between Department of Biochemistry and Department of
Obstetrics and Gynaecology, RL Jalappa Hospital and Research
Centre, Kolar, Karnataka, India. After approval from the
Institutional Ethics Committee and written informed consent from
study subjects, a total of 270 pregnant women were recruited
for this study. Among them, 135 pre-eclamptic women were
considered as cases and 135 normotensive healthy pregnant
women served as controls. According to the pre-eclampsia
severity, cases were grouped into mild (n=47) and severe preeclampsia (n=88). Blood samples were collected from all the
study subjects and was analysed for apelin 13 by Enzyme Linked
Immunosorbent Assay (ELISA) method. Maternal and foetal
adverse outcomes were recorded. Results were expressed
as mean±Standard Deviation (SD). Categorical variables were
expressed in percentages. Spearman’s correlation was applied
and p<0.05 was considered significant.
Results: The mean gestational age was 36.66±3.69 weeks
which was, significantly low in pre-eclamptic women compared
with healthy pregnant women. BMI (26.94±3.81 kg/m2
), systolic
(157.82±15.14 mmHg), diastolic (101.68±11.02 mmHg) and
Mean Arterial Pressure (MAP) (120.20±11.12 mmHg), pulse rate
(88.14±5.82 bpm), Aspartate Transaminase (AST) (25.25±12.49
IU/L) and Alanine Transaminase (ALT) (19.01±10.95 IU/L) were
significantly increased in pre-eclamptic women when compared
with control group. Mean maternal serum apelin 13 (341.44±218.63
pg/mL) concentrations were significantly lower in pre-eclampsia
compared with healthy pregnant women. Maternal serum apelin
13 concentrations were negatively correlated with Systolic Blood
Pressure (SBP) (r = -0.196), Diastolic Blood Pressure (DBP) (r
= -0.172) and MAP (r =-0.204). Adverse maternal outcomes
such as epigastric pain 75 (55.55%), oedema 62 (45.92%) and
persistent headache 35 (25.92%) were higher in pre-eclamptic
group. Additionally, adverse foetal outcomes were more in preeclamptic cases including significantly decreased birth weight
(2.40±0.65), babies requiring Neonatal Intensive Care Unit
(NICU) admission were 54 (40%), preterm birth (≤37 wks) in 50
(37.03%), Respiratory Distress Syndrome (RDS) 31 (22.96%),
Small for Gestational Age (SGA) in 4 (2.96%) and Intra Uterine
Death (IUD) in 11 (8.14%) babies.
Conclusion: It was concluded from the present study that there
was low maternal serum apelin 13 concentrations in pre-eclampsia
and had negative correlation with blood pressure, suggesting its
potential role in the pathophysiology of pre-eclampsia
Placental protein 13
Placental protein 13 (PP13), a glycan binding protein predominantly expressed in syncytiotrophoblast, dimeric in nature, lacks N-terminal signal peptide, bypasses the endoplasmic reticulum, and secretes into maternal circulation as exosomes or microvesicles. PP13 has jelly roll fold conformation with conserved carbohydrate recognition domain which specifically binds to β-galactosides of the glycan receptors during placentation. PP13 binds to glycosylated receptors on human erythrocytes and brings about hemagglutination by the property of lectin activity; other functions are immunoregulation and vasodilation during placentation and vascularization. The gene LGALS13 located on 19q13.2 comprising four exons expresses a 32-kDa protein with 139 amino acid residues, PP13. Impaired expression due to mutation in the gene leads to a nonfunctional truncated PP13. The low serum levels predict high risk for the onset of preeclampsia or obstetric complications. Hence, PP13 turned to be an early marker for risk assessment of preeclampsia. The recombinant PP13 and monoclonal antibodies availability help for replenishing PP13 in conditions with low serum levels and for detection and prevention of preeclampsia, respectively